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Technological advances in genotyping have given rise to hypothesis-
based association studies of increasing scope. As a result, the scientific
hypotheses addressed by these studies have become more complex
and more difficult to address using existing analytic methodologies.
Obstacles to analysis include inference in the face of multiple compar-
isons, complications arising from correlations among the SNPs (single
nucleotide polymorphisms), choice of their genetic parametrization
and missing data. In this paper we present an efficient Bayesian model
search strategy that searches over the space of genetic markers and
their genetic parametrization. The resulting method for Multilevel
Inference of SNP Associations, MISA, allows computation of multi-
level posterior probabilities and Bayes factors at the global, gene and
SNP level, with the prior distribution on SNP inclusion in the model
providing an intrinsic multiplicity correction. We use simulated data
sets to characterize MISA’s statistical power, and show that MISA
has higher power to detect association than standard procedures. Us-
ing data from the North Carolina Ovarian Cancer Study (NCOCS),
MISA identifies variants that were not identified by standard meth-
ods and have been externally “validated” in independent studies.
We examine sensitivity of the NCOCS results to prior choice and
method for imputing missing data. MISA is available in an R package
on CRAN.
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1. Introduction. Recent advances in genotyping technology have resulted
in a dramatic change in the way hypothesis-based genetic association stud-
ies are conducted. While previously investigators were limited by costs to
investigating only a handful of variants within the most interesting genes,
researchers may now conduct candidate-gene and candidate-pathway studies
that encompass many hundreds or thousands of genetic variants, often single
nucleotide polymorphisms (SNPs). For example, the North Carolina Ovarian
Cancer Study (NCOCS) [Schildkraut et al. (2008)], an ongoing population-
based case-control study, genotyped 2129 women at 1536 SNPS in 170 genes
on 8 pathways, where “pathway” is defined as a set of genes thought to be
simultaneously active in certain circumstances.
The analytic procedure most commonly applied to association studies of
this scale is to fit a separate model of association for each SNP that adjusts
for design and confounder variables. As false discoveries due to multiple
testing are often a concern, the level of significance for each marginal test
of association is adjusted using Bonferroni or other forms of false discovery
correction [Storey (2002); Wacholder (2004); Balding (2006)]. While these
methods have been shown to be effective in controlling the number of false
discoveries reported, correlations between the markers may limit the power
to detect true associations [Efron (2007)]. The NCOCS study provides a case
in point. When simple marginal methods are applied to the NCOCS data,
no SNPs are identified as notable.
Marginal SNP-at-a-time methods do not address directly many of the sci-
entific questions in candidate pathway studies, such as “Is there an overall
association between a pathway and the outcome of interest?” and “Which
genes are most likely to be driving this association?” The Multilevel Infer-
ence for SNP Association (MISA) method we describe here is designed to
simultaneously address these questions of association at the level of SNP,
gene and pathway.
MISA, in contrast to the marginal methods, identifies ten SNPs of interest
in the NCOCS study. To date, one of these (ranked tenth by MISA) has been
validated in external data by a large multi-center consortium [Schildkraut
et al. (2009)]; additional testing is underway for other top SNPs discovered
by MISA. To buttress this empirical evidence, we demonstrate using simu-
lation studies (Section 4) that MISA has higher power to detect associations
than other simpler procedures, with a modest increase in the false discovery
rate (Figure 1).
In the next section we describe the Bayesian hierarchical model behind
MISA and highlight how it addresses many of the key issues in analysis
of SNP association studies: identification of associated SNPs and genetic
models, missing data, inference for multi-level hypotheses and control of
the false discovery rate. Like stepwise logistic regression [Balding (2006)],
lasso [Park and Hastie (2008); Shi, Lee and Wahba (2007); Wu et al. (2009)]
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and logic regression [Ruczinski, Kooperberg and LeBlanc (2003); Kooper-
berg and Ruczinski (2004); Schwender and Ickstadt (2007)], MISA improves
upon marginal, SNP-at-a-time methods by modeling the outcome variable
as a function of a multivariate genetic profile, which provides measures of as-
sociation that are adjusted for the remaining markers. MISA uses Bayesian
Model Averaging [Hoeting et al. (1999)] to combine information from mul-
tiple models of association to address the degree to which the data support
an association at the level of individual SNPs, genes and pathways, while
taking into account uncertainty regarding the best genetic parametrization.
By using model averaging, MISA improves upon methods that select a single
model, which may miss important SNPs because of LD structure. We show
how the prior distribution on SNP inclusion provides a built-in multiplicity
correction. Because missing data are a common phenomenon in association
studies, we discuss two options for handling this problem.
In Section 3 we present an Evolutionary Monte Carlo algorithm to effi-
ciently sample models of association according to their posterior probabili-
ties. In Section 4 we apply our method to simulated data sets and demon-
strate that MISA outperforms less complex and more commonly used al-
ternatives for detecting associations in modestly powered candidate-gene
case-control studies. The simulation approach may also be used to guide se-
lection of the prior hyperparameters given the study design. In Section 5 we
return to the NCOCS study and present results from the analysis of a single
pathway from that study. We examine the sensitivity of results to prior hy-
perparameter choice and methods for imputing missing data. We conclude
in Section 6 with recommendations and a discussion of future extensions.
2. Models of association. We consider SNP association models with a
binary phenotype, such as presence or absence of a disease as in case-control
designs. For i = 1, . . . , n, let Di indicate the disease status of individual i,
where Di = 1 represents a disease case and Di = 0 represents a control.
For each individual, we have S SNP measurements, where SNP s is either
homozygous common (AsAs), heterozygous (asAs or Asas), homozygous
rare (asas), or missing and is coded as 0, 1, 2, representing the number
of rare alleles, or NA if the SNP is missing for that individual. We will
discuss methods for imputing missing SNP data in Section 2.3. In addition
to the SNP data, for each individual we have a q-dimensional vector zTi
of design and potential confounding variables that will be included in all
models, henceforth referred to as “design” variables.
We use logistic regression models to relate disease status to the design
variables and subsets of SNPs. We denote the collection of all possible mod-
els by M. An individual model, denoted by Mγ , is specified by the S
dimensional vector γ, where γs indicates the inclusion and SNP-specific ge-
netic parametrization of SNP s in model Mγ :γs = 0 if SNPs /∈Mγ , γs = 1
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if SNPs ∈Mγ with a log-additive parametrization, γs = 2 if SNPs ∈Mγ
with a dominant parametrization, and γs = 3 if SNPs ∈Mγ with a recessive
parametrization. When no homozygous rare cases or controls are observed,
we fix the genetic parametrization to be log-additive. Under each of these ge-
netic parametrizations, SNP s may be encoded using one degree of freedom.
In particular, for the log-additive model, the design variable representing
SNP s is a numeric variable equal to the number of copies of the risk allele
as. For the dominant model, we use an indicator variable of whether allele as
is present (homozygous rare or heterozygous) and for the recessive model, an
indicator variable of whether SNP s has the homozygous rare genotype. For
each individual, the logistic regression under model Mγ assuming complete
data is given by
logit(p(Di = 1|zi,xγ i,θγ ,Mγ)) = α0 + z
T
i α+ x
T
γ i
βγ ,(2.1)
where xγ i represents the coding of SNPs in model Mγ and θγ is the vector
of model specific parameters (α0,α
T ,βTγ ), with intercept α0, vector of de-
sign variable coefficients α and log-odds ratios βγ . Prospective models for
disease outcome given multivariate genetic marker data as in equation (2.1)
provide measures of association that are adjusted for other markers which
can increase the power to detect associations [Balding (2006)], however, one
is faced with an extremely large collection of possible models. While stepwise
selection methods may be used to select a single model [Cordell and Clayton
(2002)], this leads to difficulty in interpreting the significance of SNPs in the
selected model. Bayesian model averaging is an alternative to stepwise se-
lection methods and is an effective approach for identifying subsets of likely
associated variables, for prioritizing them and for measuring overall associa-
tion in the presence of model uncertainty [see the review articles by Hoeting
et al. (1999) and Clyde and George (2004) and the references therein].
2.1. Posterior inference. Posterior model probabilities measure the de-
gree to which the data support each model in a set of competing models.
The posterior model probability of any model Mγ in the space of models
M is expressed as
p(Mγ |D) =
p(D|Mγ)p(Mγ)∑
Mγ∈M
p(D|Mγ)p(Mγ)
for Mγ ∈M,
where p(D|Mγ) is the (marginal) likelihood of model Mγ obtained after
integrating out model-specific parameters θγ with respect to their prior
distribution, and p(Mγ) is the prior probability of Mγ .
While posterior probabilities provide a measure of evidence for hypothe-
ses or models, it is often difficult to judge them in isolation, as individual
model probabilities may be “diluted” as the space of models grows [Clyde
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(1999); George (1999); Clyde and George (2004)]. Bayes factors (BF) [Kass
and Raftery (1995)] compare the posterior odds of any two models (or hy-
potheses) to their prior odds
BF(Mγ1 :Mγ2) =
p(Mγ1|D)/p(Mγ2|D)
p(Mγ1)/p(Mγ2)
and measures the change in evidence (on the log scale) provided by data for
one model, Mγ1, to another, Mγ2, or for pairs of hypotheses. Goodman
(1999) and Stephens and Balding (2009) provide a discussion on the useful-
ness of Bayes factors in the medical context and Wakefield (2007) illustrates
their use in controlling false discoveries in genetic epidemiology studies. Be-
low we define Bayes factors for quantifying association at multiple levels
(global, gene and SNP) and assessing the most likely SNP-specific genetic
parametrization.
2.1.1. Global Bayes factor. The Bayes factor in favor of HA, the alter-
native hypothesis that there is at least one SNP associated with disease,
to H0, the null hypothesis that there is no association between the SNPs
under consideration and disease, measures the relative weight of evidence of
HA to H0. The null model corresponding to H0 is the model which includes
only design variables and no SNPs, and is denoted M0. The alternative
hypothesis is represented by all of the remaining models in M. Because the
space of models is large, the null model (or any single model in general)
may receive small probability (both prior and posterior), even when it is
the highest posterior probability model (this illustrates the dilution effect
of large model spaces); Bayes factors allow one to judge how the posterior
odds compare to one’s prior odds.
The Global Bayes factor for comparing HA to H0 may be simplified to
BF(HA :H0) =
∑
Mγ∈M
BF(Mγ :M0)p(Mγ |HA),(2.2)
which is the weighted average of the individual Bayes factors BF(Mγ :M0)
for comparing each model in HA to the null model with weights given by the
prior probability of Mγ conditional on being in HA, p(Mγ |HA). Because
the alternative is a composite hypothesis, the resulting Global Bayes factor
is not independent of the prior distribution on the models that comprise the
alternative, thus, the prior distribution on models will play an important role
in controlling the (relative) weights that models of different sizes receive.
For a large number of SNPs, it is impossible to enumerate the space of
models and posterior summaries are often based on models sampled from
the posterior distribution. In equation (2.2), if we replace the average over
6 M. A. WILSON ET AL.
all models in HA with the average over the models in S (the collection of
unique models sampled from the posterior distribution), the result
BF(HA :H0)> BFS(HA :H0)≡
∑
Mγ∈S
BF(Mγ :M0)p(Mγ |HA)
is a lower bound for the Bayes factor for testing global association. If the
lower bound indicates evidence of an association, then we can be confident
that this evidence will only increase as we include more models.
2.1.2. SNP Bayes factors. While it is of interest to quantify association
at the global level, interest is primarily in identifying the gene(s) and vari-
ant(s) within those genes that drive the association. We begin by defining
SNP inclusion probabilities and associated Bayes factors. These marginal
summaries are adjusted for the other potentially important SNPs and con-
founding variables and provide a measure of the strength of association at the
level of individual SNPs. Given each sampled model Mγ ∈ S and the model
specification vectors γ = (γ1, γ2, . . . , γS) previously defined in Section 2, the
inclusion probability for SNP s is estimated as
p(γs 6= 0|D) =
∑
Mγ∈S
1(γs 6=0)p(Mγ |D,S),(2.3)
where p(Mγ |D,S) is the posterior probability of a model re-normalized
over the sampled model space. The SNP Bayes factor is the ratio of the
posterior odds of the SNP being associated to the prior odds of the same,
and is defined as
BF(γs 6= 0 :γs = 0) =
p(γs 6= 0|D)
p(γs = 0|D)
÷
p(γs 6= 0)
p(γs = 0)
,
where p(γs 6= 0) is the prior probability of SNP s being associated. Estimates
of the SNP Bayes factor may be obtained using the estimated SNP inclusion
probabilities from (2.3).
2.1.3. Gene Bayes factors. In cases where there are SNPs in Linkage
Disequilibrium (LD), SNP inclusion probabilities may underestimate the
significance of an association at a given locus. This occurs because SNPs in
LD may provide competing explanations for the association, thereby diluting
or distributing the probability over several markers. Since the amount of
correlation between markers across different genes is typically negligible,
calculating inclusion probabilities and Bayes factors at the gene level will
not be as sensitive to this dilution. A gene is defined to be associated if one
or more of the SNPs within the given gene are associated. Hence, we define
the gene inclusion probability as
p(Γg = 1|D) =
∑
Mγ∈S
1(Γg=1)p(Mγ |D,S),
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where Γg = 1 if at least one SNP in gene g is in model Mγ and is zero
otherwise. The gene Bayes factor is defined as
BF(Γg = 1 :Γg = 0) =
p(Γg = 1|D)
p(Γg = 0|D)
÷
p(Γg = 1)
p(Γg = 0)
,
where p(Γg = 1) is the prior probability of one or more SNPs in gene g being
associated.
2.1.4. Interpreting evidence. Jeffreys [(1961), page 432], presents a de-
scriptive classification of Bayes factors into “grades of evidence” (reproduced
in Table 1) to assist in their interpretation [see Kass and Raftery (1995)]. In
the context in which he presents the grades, he defined the Bayes factor as-
suming equal prior odds, making it equivalent to posterior odds and enabling
a meaningful interpretation in terms of probabilities. It is not clear whether
he intended his descriptive grades to be used more broadly for interpreting
Bayes factors or for interpreting posterior probabilities.
Jeffreys was well aware of the issues that arise with testing several sim-
ple alternative hypotheses against a null hypothesis [Jeffreys (1961), Sec-
tion 5.04], noting that if one were to test several hypotheses separately, that
by chance one might find one of the Bayes factors to be less than one even if
all null hypotheses were true. He suggested that, in this context, the Bayes
factors needed to be “corrected for selection of hypotheses” by multiplying
by the prior odds.
Experience has shown that detectable SNP associations are relatively in-
frequent, hence, the prior odds of any given SNP being marginally associ-
ated in the typical genetic association study should be small. For this reason,
Stephens and Balding (2009) suggest that marginal Bayes factors calculated
assuming equal prior odds be interpreted in light of a prior odds more ap-
propriate to the study at hand. Our approach to the problem of exploring
multiple hypotheses is to embed each of the potential submodels (corre-
sponding to a subset of SNPs) into a single hierarchical model. Unlike the
marginal (one-at-a-time) Bayes factors in Stephens and Balding (2009) that
are independent of the prior odds on the hypotheses, our SNP Bayes factors
are based on comparing composite hypotheses and hence do depend on the
prior distribution over models, which implicitly adjusts for the selection of
hypotheses.
While Bayes factors do not provide a measure of absolute support for or
against a hypothesis (except with even prior odds), the log Bayes factor does
provide a coherent measure of how much the data change the support for the
hypothesis (relative to the prior) [Lavine and Schervish (1997)]. Applying
Jeffreys grades to Bayes factors using priors distributions that account for
competing hypotheses provides an idea of the impact of the data on chang-
ing prior beliefs, but ultimately posterior odds provide a more informative
measure of evidence and model uncertainty.
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Table 1
Jeffrey’s grades of evidence [Jeffreys (1961), page 432]
Grade BF(HA :H0) Evidence against H0
1 1 – 3.2 Indeterminate
2 3.2 – 10 Positive
3 10 – 31.6 Strong
4 31.6 – 100 Very strong
5 >100 Decisive
2.2. Prior distributions, Laplace approximations and marginal likelihoods.
We assume normal prior distributions for the coefficients θγ with a covari-
ance matrix that is given by a constant 1/k times the inverse Fisher In-
formation matrix. For logistic regression models, analytic expressions for
p(D|Mγ) are not available and Laplace approximations or the Bayes Infor-
mation Criterion are commonly used to approximate the marginal likelihood
[Raftery (1986); Wakefield (2007); Burton et al. (2007)]. Using a Laplace ap-
proximation with the normal prior distribution [Wilson et al. (2010)], the
posterior probability of model Mγ takes the form of a penalized likelihood
p(Mγ |D)∝ exp{−
1
2 [dev(Mγ ;D) + pen(Mγ)]},(2.4)
where dev(Mγ ;D) =−2 log(p(D|θˆγ ,Mγ)) is the model deviance, and the
penalty term pen(Mγ) encompasses a penalty on model size induced by
the choice of k in the prior distribution on coefficients θγ and the prior
distribution over models. Because we expect that effect sizes will be small, we
calibrate the choice of k based on the Akaike information criterion [Wilson
et al. (2010)], leading to
pen(Mγ) = 2(1 + q + sγ)− 2 log(p(Mγ)).
2.3. Missing data. The expression in (2.4) assumes complete data on all
SNPs. Missing SNP data, unfortunately, are the norm rather than the ex-
ception in association studies. Removing all subjects with any missing SNP
genotype data will typically result in an unnecessary loss of information
and potential bias of estimated effects if the missing data are nonignorable.
It is possible, however, to exploit patterns in LD to efficiently impute the
missing genotypes given observed data [Balding (2006)]. We use fastPHASE
[Stephens, Smith and Donnelly (2001); Servin and Stephens (2007)] to sam-
ple haplotypes and missing genotypes (Gm) given the observed unphased
genotypes (Go). This assumes that the pattern of missing data is indepen-
dent of case-control status, which, if not true, may lead to serious biases
[Clayton et al. (2005)]. This assumption may be examined by using indica-
tor variables of missingness as predictors in MISA.
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The posterior probabilities of models given the data are obtained by av-
eraging the marginal likelihood of a model over imputed genotype data:
p(Mγ |D)∝
∫
exp{−12 [dev(Mγ ;D,G
o,Gm)
+ pen(Mγ)]}p(G
m|Go)dGm
(2.5)
≈
1
M
I∑
i=1
exp{−12 [dev(Mγ ;G
o,Gmi ) + pen(Mγ)]}
≡Ψ(Mγ),
where I is the number of imputed data sets, dev(Mγ ;D,G
o,Gm) is the
deviance based on the completed data, and Ψ(Mγ) is an estimate of the
un-normalized posterior model probability for model Mγ . We have found
that the number of imputed sets must be on the order of I = 100 to provide
accurate estimates of posterior quantities. This has a significant computa-
tional impact in the model search algorithm described in Section 3. As a
simple alternative, we approximate (2.5) by a modal approximation, where
the missing genotypes are imputed with the mode of the sampled genotypes
using fastPHASE. While it is well known that plugging in a single estimate
for the missing data under-estimates uncertainty, the modal approximation
provides dramatic computational savings. In Section 5 we examine the sen-
sitivity of results to the method of imputing missing data and find that the
modal approximation gives comparable results for SNP BFs.
2.4. Choice of prior distribution on models. The prior distribution on
the space of models M, p(Mγ), completes our model specification. The fre-
quentist approach for SNP association studies usually involves some form of
adjustment for multiple-testing, which can, in effect, penalize the researcher
who looks beyond single-SNP models of association to multiple SNP models
or models of interactions. Under the Bayesian approach, posterior evidence
in the data is judged against the prior odds of an association using Bayes
factors, which should not be affected by the number of tests that an inves-
tigator chooses to carry out [Balding (2006)].
While it has been common practice to adopt a “noninformative” uniform
distribution over the space of models for association (this is after marginal-
izing over the possible genetic models for each SNP), this choice has the
potentially undesirable “informative” implication that 12 of the SNPs are
expected to be associated a priori, and the prior odds of at least one SNP
being included (which is used in the global Bayes factor) depends on the
number of tests (2S) (Table 2).
10 M. A. WILSON ET AL.
A recommended alternative is the Beta-Binomial distribution on the model
size, which provides over-dispersion, added robustness to prior misspecifica-
tion and multiplicity corrections as a function of the number of variables
[Ley and Steel (2009); Scott and Berger (2010); Cui and George (2008)].
We construct a hierarchical prior distribution over the space of models de-
fined by subsets of SNPs and their genetic parametrizations as follows. For
any SNP included in the model, we assign a uniform distribution over the
possible genetic parametrizations. The prior distribution on the model size
sγ is Bin(S,ρ) conditional on ρ, and for the last stage, ρ is assigned a
Beta(a, b) distribution. Integrating over the distribution on ρ leads to the
BetaBinomial(a, b) distribution on model size,
p(sγ) =
B(sγ + a,S − sγ + b)
(S +1)B(sγ + 1, S − sγ + 1)B(a, b)
,(2.6)
and the following distribution on models,
p(Mγ) =
(
1
3
)sγ B(sγ + a,S − sγ + b)
B(a, b)
,(2.7)
where B(·, ·) is the beta function and the factor of 1/3 accounts for the
distribution over genetic parametrizations.
2.4.1. Default hyperparameter choice. Following Ley and Steel (2009)
and Scott and Berger (2010), we recommend a= 1 as a default, so that the
prior distribution on model size is nonincreasing in sγ . The hyperparameter
b can then be chosen to reflect the expected model size, the global prior prob-
ability of at least one association or the marginal prior odds that any SNP
is associated (Table 2). A default choice is to set b= 1, leading to a uniform
distribution on model size [Ley and Steel (2009); Scott and Berger (2010)].
Like the binomial distribution, the BetaBinomial(1,1) distribution results
Table 2
General prior characteristics and limiting behavior (in parentheses) of the Bin(S,1/2),
BetaBinomial(1,1) and BetaBinomial(1, λS) distribution on model size
Binomial Beta-Binomial Beta-Binomial
(S,1/2) (1,1) (1, λS)
Expected model size S
2
(∞) S
2
(∞) S
λS+1
( 1
λ
)
Global prior odds 2
2S
2S+1
(∞) S (∞) 1
λ
of an association
Marginal prior odds 1 1 1
λS
(0)
of an association
Prior odds of adding a variable 1
sγ+1
S−sγ
(0)
sγ+1
(λ+1)S−sγ−1
(0)
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in an expected model size of S2 (Table 2), although the BetaBinomial(1,1)
distribution has a larger variance than the Bin(S,1/2). Alternatively, if b is
proportional to S, b= λS, the expected model size approaches a limit of 1
λ
as S approaches infinity.
The choices for hyperparameters have implications for the global Bayes
factor. The BetaBinomial(1,1) has a global prior odds of association equal
to the number of SNPs, S, and would be appropriate for the case where
increasing the number of SNPs under consideration reflects increased prior
certainty that an overall (global) association can be detected. Under the
BetaBinomial(1, λS), the global prior odds are constant, 1/λ, reflecting a
prior odds for overall association that is independent of the number of
genes/SNPs tagged. Also, with both Beta–Binomial prior distributions, the
prior odds of incorporating an additional SNP in any model decreases with
model size sγ and approaches 0 in the limiting case as the number of SNPs,
S, increases. This provides an implicit multiple testing correction in the num-
ber of SNPs (rather than tests) that are included in the study of interest.
The BetaBinomial(1, λS) achieves this by keeping the global (pathway) prior
odds of an association constant while decreasing the marginal prior odds of
any one of the SNPs being associated as the number of SNPs increases. As
a skeptical “default” prior, we suggest the hyperparameters a= 1 and b= S
which leads to the global prior odds of there being at least one association
of 1 and the marginal prior odds of any single SNP being associated of 1/S.
3. Stochastic search for SNPs. Given the number of SNPs under consid-
eration, enumeration of all models for S greater than 25–30 is intractable.
While it is possible to enumerate all single variable SNP models, the number
of models with 2 or 3 SNPs allowing for multiple genetic parametrizations
is in the millions or more for a typical modern hypothesis-oriented study.
Stochastic variable selection algorithms [see Clyde and George (2004), for a
review] provide a more robust search procedure than stepwise methods, but
also permit calculation of posterior probabilities and Bayes factors based on
a sample of the most likely candidate models from the posterior distribution.
MISA makes use of a stochastic search algorithm based on the Evolution-
ary Monte Carlo (EMC) algorithm of Liang and Wong (2000). EMC is a
combination of parallel tempering [Geyer (1991)] and a genetic algorithm
[Holland (1975)] and samples models based on their “fitness.” While origi-
nally designed to find optimal models based on AIC, in our application the
fitness of the models is given by ψ(Mγ),
ψ(Mγ) = log(Ψ(Mγ)),
where Ψ(Mγ) is defined in equation (2.5) and is equal to the log of the un-
normalized posterior model probability. This results in models being gener-
ated according to their posterior probability.
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The EMC algorithm requires that we specify the number of parallel chains
that are run and the associated temperature for each chain that determines
the degree of annealing. If the temperatures are too spread out for the num-
ber of chains, then the algorithm may exhibit poor mixing and slow con-
vergence. Liang and Wong (2000) show that even with all chains run at
a temperature of 1 (no annealing), EMC outperforms alternative sampling
methods such as Gibbs sampling and Reversible Jump MCMC in problems
where strong correlations among the predictor variables lead to problems
with exploring multiple modes in the posterior distribution. We have found
that a constant temperature ladder with 5 parallel chains provides good mix-
ing and finds more unique models than using a custom temperature ladder
based on the prescription in Liang and Wong (2000), and recommend the
constant temperature ladder as a default. To assess convergence, we take
two independent EMC runs using randomly chosen starting points and ex-
amine trace plots of the fitness function. We use the marginal likelihoods
from the set of unique models in the sample for inference and compute esti-
mates of marginal posterior inclusion probabilities for each run. We continue
running the two instances of the EMC algorithm until the posterior proba-
bilities derived from each are sufficiently close. This leads to longer running
times than those suggested by conventional convergence diagnostic such as
Gelman–Rubin [Gelman and Rubin (1992)].
Efficiency of stochastic algorithms often diminishes as the total number
of models increases. For this reason, we have found it useful to reduce the
number of SNPs included in the EMC search using a screen when S is large.
Such a screen will typically be fairly permissive, leaving only the weak-
est candidates out of the stochastic search. The screen should be quick to
calculate, adjust for the same design variables and consider the same ge-
netic parametrizations as in the full analysis. In our analyses, we calculated
marginal (i.e., SNP-at-a-time) Bayes factors for each of the log-additive,
dominant and recessive models of association against the model of no asso-
ciation. We ordered SNPs according to the maximum of the three marginal
Bayes factors and retained those with a maximum marginal BF greater than
or equal to one. More details are available in Wilson et al. (2010).
4. Simulation comparison. We used the 124 simulated case-control data
sets [details of the simulation can be found in Wilson et al. (2010)] to es-
timate true and false positive rates for MISA and seven other alternative
procedures:
Bonferroni We fit a logistic regression model for each SNP under the log-
additive parametrization and calculate the p-value for testing association
using a Chi-Squared test. We use a Bonferroni corrected level α= 0.05 test
to declare a SNP associated.
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Adjusted Bonferroni We fit a logistic regression model for each SNP un-
der the log-additive parametrization and calculate the p-value for testing
association using a Chi-Squared test. We use a Bonferroni corrected level
α test to declare a SNP associated where α is chosen so that the propor-
tion of false positives detected is the same as in MISA using the default
BetaBinomial(1, S) prior.
Benjamini–Hochberg We fit the same SNP-at a time logistic regression as
above, but declare a SNP to be associated if it has a Benjamini–Hochberg
false discovery rate of less than 0.05.
Marginal BF This also utilizes the single SNP at a time logistic regres-
sion, but calculates a BF for association under each of the three genetic
models. If the maximum BF over the three genetic models is greater than
3.2, we declare the SNP associated. See Wilson et al. (2010) for more detail.
Stepwise LR (AIC) We use a stepwise multiple logistic regression proce-
dure to select SNPs based on AIC. Each SNP is coded using 2 degrees of
freedom to select among the three genetic models. SNPs in the final model
are called associated.
Stepwise LR (BIC) Same as above but using BIC to select models.
Lasso We use the Lasso2 package in R [Lokhorst et al. (2009)] that is
based on the algorithm developed by Osborne, Presnell and Turlach (2000)
to select SNPs based on the least absolute shrinkage and selection operator.
Each SNP is coded using 2 degrees of freedom to represent the three genetic
models and all SNPs in the final model with coefficients greater than zero
are called associated.
MISA We reduced the number of SNPs using the marginal Bayes factor
method above to eliminate SNPs with a marginal BF ≥ 1. We ran MISA
using the default BetaBinomial(1, S) and the BetaBinomial(1/8, S) prior dis-
tributions on the models using two runs of 400,000 iterations based on con-
vergence of the marginal inclusion probabilities. SNPs are called associated
if their MISA SNP BF is greater than 3.2. All SNPs that did not pass the
marginal screen step in MISA were declared not associated.
The first four are single SNP methods, while the last three are multi-SNP
methods that take into account the genetic parametrization for each SNP.
Figure 1 shows the proportion of SNPs detected by each of the methods
as a function of the assumed true odds ratio. Thus, at an odds ratio of 1.00
we plot the proportion of SNPs that were falsely declared associated by
each of the methods. While both Bonferroni and Benjamini–Hochberg have
the smallest false positive rates, they have much lower power to detect true
associations than any of the other methods; the marginal BF has the highest
power out of the three marginal methods, and is comparable to lasso, a multi-
SNP method. Stepwise model selection using BIC has the lowest power of
the multiple SNP model selection procedures. Stepwise logistic regression
14 M. A. WILSON ET AL.
Fig. 1. True and false positive rates of MISA versus alternative methods.
using AIC to select a model, on the other hand, has high power to detect
associations, but an unacceptably high false positive rate (44%). With the
exception of stepwise/AIC, the MISA methods have higher power than the
alternatives at all odds ratios (ORs) in the simulation, with the gain in
power most noticeable for the smaller ORs, those encompassing the range
1.25–1.75 typically seen in practice [Flint and Mackay (2009)]. This increase
in power comes at the cost of only a slight increase in the false positive rate.
Overall, MISA using the default BetaBinomial(1, S) prior distribution is able
to detect 9% as many associations at the SNP level and 13% as many at
the gene level than the marginal BF method used alone. In addition, MISA
is able to detect 19% as many true associations at the SNP level and 27%
as many at the gene level as the calibrated Bonferroni method (the two
methods have the same Type I error rate).
4.1. Sensitivity to hyperparameters. We examined a range of parameters
(a and b) for the Beta-Binomial prior distribution on model size (Table 3)
to assess sensitivity of true positive and false positive rates. In practice, this
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may be done by reweighting the MCMC output using the new prior distribu-
tion, without resorting to additional MCMC runs, as long as high posterior
probability models receive adequate support under both prior distributions.
Over the range of values for (a, b), MISA has a higher gene and SNP true
positive rate than any of the other simpler procedures, with the exception
of Stepwise AIC. In general, decreasing a leads to higher true positive rates,
but at the expense of higher false positive rates. The SNP false positive
Table 3
Estimated overall false and true positive rates with standard errors and prior odds (PO)
of association at the gene and SNP levels. The values in bold characterize the method
selected for use in the analysis of the NCOCS ovarian cancer example
Method: True positive False positive PO of assoc.
Gene (se) SNP (se) Gene (se) SNP (se) Global SNP
n: 1020 1020 5546 54980
MISA
a b
1 1
2
S 0.77 (0.006) 0.669 (0.007) 0.128 (0.001) 0.025 (0.0001) 2.00 0.04
1/2 · 0.809 (0.005) 0.704 (0.007) 0.166 (0.001) 0.031 (0.0001) 0.74 0.020
1/4 · 0.846 (0.004) 0.729 (0.006) 0.189 (0.001) 0.041 (0.0002) 0.32 0.009
1/8 · 0.874 (0.003) 0.739 (0.006) 0.259 (0.001) 0.048 (0.0002) 0.15 0.005
1/16 · 0.896 (0.003) 0.746 (0.006) 0.341 (0.001) 0.065 (0.0003) 0.07 0.002
1/32 · 0.904 (0.003) 0.746 (0.006) 0.437 (0.001) 0.090 (0.0003) 0.04 0.001
1 S 0.784 (0.005) 0.685 (0.007) 0.150 (0.001) 0.027 (0.0001) 1.00 0.020
1/2 · 0.821 (0.005) 0.716 (0.006) 0.185 (0.001) 0.035 (0.0001) 0.42 0.009
1/4 · 0.855 (0.004) 0.736 (0.006) 0.207 (0.001) 0.044 (0.0002) 0.19 0.005
1/8 · 0.877 (0.003) 0.743 (0.006) 0.280 (0.001) 0.053 (0.0002) 0.09 0.002
1/16 · 0.899 (0.003) 0.746 (0.006) 0.368 (0.001) 0.073 (0.0003) 0.04 0.001
1/32 · 0.904 (0.003) 0.746 (0.006) 0.465 (0.001) 0.098 (0.0004) 0.02 0.001
1 3
2
S 0.791 (0.005) 0.696 (0.007) 0.169 (0.001) 0.029 (0.0001) 0.67 0.01
1/2 · 0.825 (0.005) 0.722 (0.006) 0.190 (0.001) 0.037 (0.0002) 0.29 0.006
1/4 · 0.855 (0.004) 0.735 (0.006) 0.222 (0.001) 0.048 (0.0002) 0.14 0.003
1/8 · 0.878 (0.003) 0.744 (0.006) 0.291 (0.001) 0.057 (0.0002) 0.07 0.002
1/16 · 0.898 (0.003) 0.746 (0.006) 0.377 (0.001) 0.075 (0.0003) 0.03 0.001
1/32 · 0.902 (0.003) 0.746 (0.006) 0.474 (0.001) 0.099 (0.0004) 0.02 0.0004
Marg. BF 0.695 (0.007) 0.627 (0.007) 0.171 (0.001) 0.041 (0.0002) – 1.00
lasso 0.708 (0.007) 0.607 (0.008) 0.158(0.001) 0.022 (0.0001) – –
Step. AIC 0.993 (0.000) 0.794 (0.005) 0.969 (0.0001) 0.445 (0.001) – –
Step. BIC 0.680 (0.007) 0.547 (0.008) 0.122(0.001) 0.015 (0.0001) – –
BH 0.439 (0.008) 0.419 (0.008) 0.013 (0.0001) 0.011 (0.0001) – –
Bonf. 0.337 (0.007) 0.330 (0.008) 0.003 (0.00001) 0.006 (0.00002) – –
Adj. Bonf. 1 0.618 (0.007) 0.574 (0.008) 0.069 (0.0003) 0.027 (0.0001) – –
Adj. Bonf. 2 0.708 (0.007) 0.644 (0.007) 0.184 (0.001) 0.053 (0.0002) – –
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rate is modest, ranging from 0.025 to 0.099, providing effective control of
the experiment wide error rate. While these rates are higher than the false
positive rates under Bonferroni or Benjamini–Hochberg, eliminating a SNP
from consideration that truly is associated has a higher scientific cost than
continuing to collect data to confirm that a SNP is really a null finding.
Because the NCOCS will follow up apparent associations, a higher true
positive rate with a modest increase in false positives was preferable.
The hyperparameters a= 1/8 and b= S, highlighted in bold in Table 3,
were selected for comparison with the default choice (a = 1, b = S) in the
analysis of the NCOCS data presented in the next section. MISA using the
BetaBinomial(1/8, S) is able to detect 19% as many true associations at the
SNP level and 26% as many at the gene level as the marginal BF method
used alone. In addition, MISA with the BetaBinomial(1/8, S) prior is able to
detect 14% as many true associations at the SNP level and 24% as many at
the gene level as a calibrated Bonferroni method (the two methods have the
same Type I error rate).
5. Ovarian cancer association analysis. In this section we describe a
MISA candidate pathway analysis of data from the ongoing NCOCS ovar-
ian cancer case-control association study. The NCOCS is a population based
study that covers a 48 county region of North Carolina [Schildkraut et al.
(2008)]. Cases are between 20 and 74 years of age and were diagnosed with
primary invasive or borderline epithelial ovarian cancer after January 1,
1999. Controls are frequency matched to the cases by age and race and have
no previous diagnosis of ovarian cancer. In the analysis we present, we focus
on self-reported Caucasians and a specific histological subtype of the cancer,
leaving us a total of 397 cases and 787 controls. Because the ovarian cancer
results have not yet been published, we have anonomyzed the pathway, the
genes chosen to represent it and the IDs of the SNPs tagging variation in
those genes. The pathway is comprised of 53 genes tagged by 508 tag SNPs.
All models fit in the screen and by MISA included the patient’s age as
a design variable. We used the modal approximation to fill in missing SNP
data. We screened 508 SNPs using marginal Bayes factors, retaining S = 70
SNPs that exceeded the threshold of 1 in favor of an association. Using
the default hyperparameters a= 1 and b= S, we ran two independent runs
of the algorithm from independent starting points for a total of 1.2 mil-
lion iterations—the point at which the SNP marginal inclusion probabilities
from the two independent runs were determined to be in sufficiently close
agreement.
On the basis of this analysis, we estimate a lower bound on the pathway-
wide Bayes factor for association to be BF(HA :H0) = 7.67 (which is also
the posterior odds for this prior). This constitutes “positive” evidence in
favor of an association between the pathway and ovarian cancer based on
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Fig. 2. Image plot of the SNP inclusion indicators for the SNPs with marginal Bayes
factors greater than 3.2 and the top 100 Models. The color of the inclusion block corre-
sponds to the genetic parametrization of the SNP in that model. Purple corresponds to
a log-additive parametrization, red to a dominant parametrization and blue to a reces-
sive parametrization. SNPs are ordered on the basis of their marginal SNP Bayes factors
which are plotted on the right axis across from the SNP of interest. Width of the column
associated with a model is proportional to its estimated model probability.
Jeffreys’ grades of evidence and corresponds to a posterior probability that
the pathway is associated of roughly 0.89. Figure 2 summarizes the associ-
ations of the ten SNPs that had a SNP BF greater than 3.2, while Figure 3
illustrates the nine genes that contained these SNPs and two others that
received comparable support. SNPs and genes in the pathway are denoted
by a two-level name (e.g., S1 and G1) where the number represents the rank
of the SNP or gene by its respective Bayes factor. These plots provide a
graphical illustration of the top 100 models Mγ ∈M selected on the basis
of their posterior model probabilities. Models are ordered on the x-axis in
descending probability and the width of the column associated with a model
is proportional to that probability. SNPs (Figure 2) or genes (Figure 3) are
represented on the y-axis. The presence of a SNP or gene in a model is
indicated by a colored block at the intersection of the model’s column and
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Fig. 3. Image plot of the gene inclusion indicators for the top 100 Models. Genes are
ordered based on their marginal gene Bayes factors which are plotted on the right axis.
Columns correspond to models and have width proportional to the estimated model proba-
bility, models are plotted in descending order of posterior support. The color is chosen to
be neutral since the genetic parametrizations are not defined at the gene level.
the SNP’s or gene’s row. In Figure 2 the color of the block indicates the
parametrization of the SNP: purple for log-additive, blue for recessive and
red for dominant. The “checkerboard” pattern (as opposed to the presences
of more vertical bars) suggests substantial model uncertainty.
The top five models depicted in Figure 2 include only a single SNP in
addition to age at diagnosis (the design variable is omitted in the figure
as it is included in all models). The top model includes SNP S1 in gene
G1 under the log-additive genetic parametrization, which is estimated to
have an odds ratio (OR) of approximately 1.42 (the posterior mode). The
second ranked model includes only SNP S2 in gene G1 under the log-additive
genetic parametrization with an estimated OR of 1.37. Note that the study
has relatively low power to detect effects of this magnitude (Figure 1).
Figure 2 also illustrates that many of the top models beyond the first five
include multiple SNPs. This suggests that if we were to restrict our attention
to single SNP models, we would potentially lose substantial information
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regarding their joint effects. For example, model six is comprised of both
SNP S3 from gene G5 and SNP S1 from gene G1, while model 12 is comprised
of both SNP S3 from gene G5 and SNP S2 from gene G2. In both cases,
SNP S3 is included in models with a SNP from gene G1. This may indicate
that not only are SNPs S1, S2 and S3 important as single effects in the top
four models, but that their combined effects may be of interest. Note that, in
cases where the disease variant is unmeasured but “tagged,” several tagged
SNPs may be required to explain variation at that locus.
The SNP Bayes factors of S1 (BF = 42.2) and S2 (BF = 17.8) provide
“strong evidence” of changes in prior beliefs, however, the marginal pos-
terior probabilities of association with ovarian cancer are 0.38 and 0.20,
respectively. Figure 2 illustrates that when one of SNP S1 or S2 is included
in a model, the other is often not (at least in the top 50 models). This trade
off often arises when SNPs are correlated (i.e., in high linkage disequilib-
rium). In this case, R2 is 0.5 suggesting fairly strong LD between SNPs
S1 and S2, in which case the joint inclusion probabilities are more mean-
ingful than marginal probabilities. Both SNP 1 and SNP 2 are in gene G1
which has a gene Bayes factor of 31.95 (Figure 3) and posterior probabil-
ity of association of 0.58. These probabilities need to be interpreted in the
context of model uncertainty; conditional on the pathway being associated
with ovarian cancer, the probability that gene G1 is driving the association
is 0.58/0.89 = 0.65. However, there remains substantial uncertainty regard-
ing which genes and SNPs may explain it, as the posterior mass is spread
over competing models/hypotheses. The positive support for an association
suggests the continuation of data accrual to refine these posterior probabil-
ities.
Gene G1 and other genes in Figure 3 highlight a caution regarding the
interpretation of Bayes factors as a measure of absolute support with com-
posite hypotheses. The gene Bayes factor for G1 is 31.95, which is smaller
than the SNP Bayes factors for S1 (42.2). The posterior probability that
gene G1 is associated is based on summing the probabilities of all models
that include at least one SNP from that gene (S1, S2 and S51), hence, the
posterior probability for gene inclusion is always greater than or equal to
the probability that any one SNP is included (i.e., posterior probabilities
observe a monotonicity property with composite hypotheses). Bayes fac-
tors (and p-values) for composite hypotheses do not share this monotonicity
property [Lavine and Schervish (1997)]. Bayes factors for comparing com-
posite hypotheses may be expressed as the ratio of the weighted average
(with respect to the prior distribution) of marginal likelihoods conditional
on the hypotheses, which may decrease the evidence in favor of a composite
hypothesis when a subset of the individual hypotheses have low likelihood.
As mentioned in Section 2.1.4, while Bayes factors do not provide a coher-
ent measure of absolute support because of their nonmonotonicity property,
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Lavine and Schervish (1997) show that the log Bayes factor does provide
a coherent measure of how much the data change the support for the hy-
pothesis (relative to the prior). Hence, they do provide useful summaries of
changes in prior beliefs of association in large association studies with many
competing models/hypotheses.
5.1. Sensitivity analysis. In this section we consider sensitivity of the
results in the NCOCS study to the prior distribution on the models and to
the method of imputation. The simulation study suggests that priors with
smaller values of a may identify more associated SNPs. We estimated that
the BetaBinomial(1/8, S) prior distribution on model size has a false posi-
tive rate comparable to the marginal BF method, but a much higher true
positive rate, in the scenarios we considered. Full data imputation, achieved
by averaging over the distribution of missing SNPs, is probabilistically cor-
rect, but computationally expensive. Thus, if the use of modal imputation
provides an accurate approximation to BF calculated using full imputation,
the computational efficiency of MISA can be greatly improved at small cost.
For purposes of this analysis, we used the set of unique models iden-
tified by the EMC search with modal imputations and a = 1 and calcu-
lated 3 additional sets of BFs. First, we obtained marginal likelihoods for
each of these models using 100 imputed data sets with missing SNPs filled
in based on their estimated distribution. Second, we calculated BFs using
the BetaBinomial(1/8, S) and BetaBinomial(1, S) prior distributions using
the marginal likelihoods under the full and modal imputations. We applied
ANOVA to these four sets of BFs to compare the effects of prior hyperpa-
rameters and imputation methods after adjusting for SNP using the ranked
SNP BFs.4
Table 4 shows that the method of imputation has no significant effect on
the ranking of SNP BFs. This suggests that, for purposes of model search
and calculation of BFs, we may use the modal imputed genotypes in place
of full imputation, with significant computational savings. For purposes of
parameter estimation, we suggest that the use of full imputation using a
subset of the top models and top SNPs as using a plug-in approach for
imputation is known to underestimate uncertainty.
We anticipated that the prior distribution would have a significant effect
based on the higher true positive and false positive rates estimated from
the simulation study and by considering differences in the prior odds. While
Table 4 suggests that overall the rankings are different between the two
prior distributions, the top 20 SNPs have the same rank under each of the
4Ranks that were used as residuals on the log scale still exhibited strong departures
from normality.
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four methods, leading to no qualitative differences in our conclusions about
the top SNPs. The prior odds for any given SNP’s inclusion in a model
are 8 times lower under the BetaBinomial(1/8, S) prior distribution than
under to the BetaBinomial(1, S) prior distribution; the resulting SNP BFs
are 2.8 times higher under the BetaBinomial(1/8, S) prior distribution than
those under the BetaBinomial(1, S) prior distribution. As a result, eight more
SNPs are above the 3.2 threshold used by the NCOCS to determine SNPs
worthy of additional study.
5.2. External validation and comparison. To provide a basis of compar-
ison, we applied the methods described in the simulation study (Section 4)
to the NCOCS data. We omitted stepwise logistic regression using AIC be-
cause of its poor operating characteristics. The marginal FDR methods of
Bonferroni and Benjamini–Hochberg failed to identify any significant SNPs.
Lasso, which accounts for correlation among SNPS, also failed to identify any
SNPS. Stepwise logistic regression using BIC selected a model with three
of the top four SNPs identified by MISA—S1.G1, S3.G5 and S4.G4—but
failed to identify S2.G1, which has correlation 0.71 with SNP S1.G1. This
highlights a problem with selection methods that ignore model uncertainty.
The NCOCS proposed two SNPs—S10 and S14 in G9—for external val-
idation by the Ovarian Cancer Association Consortium (OCAC), a large
international multi-center consortium of ovarian cancer case-control stud-
ies. The decision to focus on these variants was made on the basis of results
from an earlier version of the NCOCS data set and on the basis of the strong
prior interest NCOCS researchers had in the gene (and not on the basis of
the analysis described above). Under the default BetaBinomial(1, S) prior
distribution, only SNP S10 in G9 exceeds the 3.2 threshold and the G9 BF
is only 2.28. In contrast, under the BetaBinomial(1/8, S) prior distribution,
both SNPs S10 and S14 (LD 0.62) in G9 have SNP BFs greater than 3.2
(8.70 and 5.99, respectively) and the gene BF is 6.18. An additional three
Table 4
Analysis of variance for the ranked SNP Bayes factors contrasting the prior
hyperparameters (default a= 1 versus a= 1/8) and method of imputation (full
imputation with 100 data sets versus a modal estimate of the missing genotypes) for the
70 SNPs in the NCOCS pathway that passed the marginal screen
d.f. Sum Sq. Mean Sq. F -value Pr(>F )
SNP 69 1635891.00 23708.57 208.04 <2× 10−16
Prior 1 169641.66 169641.66 1488.60 0.0000
Impute 1 134.41 134.41 1.18 0.28
Prior:impute 1 53.16 53.16 0.47 0.50
Residuals 207 23589.77 113.96
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SNPs in the same gene were proposed by another member of the consortium
on the basis of uncorrected p-values. Of the five SNPs proposed for valida-
tion, only SNPs S10 and S14 were confirmed to be associated with serous
invasive ovarian cancer by OCAC [Schildkraut et al. (2009)].
6. Discussion. In this paper we describe MISA, a natural framework for
multi-level inference with an implicit multiple comparisons correction for hy-
pothesis based association studies. MISA allows one to quantify evidence of
association at three levels: global (e.g., pathway-wide), gene and SNP, while
also allowing for uncertainty in the genetic parametrization of the markers.
We have evaluated MISA against established, simple to implement and more
commonly used methods and demonstrated that our methodology does have
higher power than these methods in detecting associations in modestly pow-
ered candidate pathway case-control studies. The improvement in power is
most noticeable for odds ratios of modest (real world) magnitude and comes
at the cost of only a minimal increase in the false positive rate. Like stepwise
logistic regression, lasso and logic regression, MISA improves upon marginal,
SNP-at-a-time methods by considering multivariate adjusted associations.
By using model averaging, MISA improves upon these multivariate meth-
ods that select a single model, which may miss important SNPs because
of LD structure. These improvements have concrete implications for data
analysis: MISA identified SNPs in the NCOCS data that were subsequently
externally validated; none of the less complex methods considered here high-
lighted these SNPs to be of interest. Currently, other top ranked SNPs in
genes identified by MISA are undergoing external validation. Finally, we
note that while MISA was developed for binary outcomes in case-control
studies, MISA is readily adaptable to accommodate other forms of outcome
variables (e.g., quantitative traits or survival) that are naturally modeled
within a GLM framework.
Web resources. The URL for the software for the methodology and sim-
ulations presented in this paper is as follows: http://www.isds.duke.edu/
gbye/packages.html.
SUPPLEMENTARY MATERIAL
Bayesian model search and multilevel inference for SNP association stud-
ies: Supplementary materials (DOI: 10.1214/09-AOAS322SUPP; .pdf). In
this supplement we provide details for: (1) Derivation of the implied prior
distribution on the regression coefficients when AIC is used to approximate
the marginal likelihood in logistic regression, (2) Description of the marginal
Bayes factor screen used to reduce the number of SNPs in the MISA anal-
ysis, (3) Details of how the simulated genetic data sets used in the power
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analysis of MISA were created and information on the statistical software we
developed for this purpose, and (4) Location of the freely available software
resources referred to in this and the parent document.
REFERENCES
Balding, D. J. (2006). A tutorial on statistical methods for population association stud-
ies. Nature 7 781–791.
Clayton, D. G., Walker, N. M., Smyth, D. J. and Pask, R. (2005). Population
structure differential bias and genomic control in a large-scale casecontrol association
study. Nature Genet. 37 1243–1246.
Clyde, M. (1999). Bayesian model averaging and model search strategies (with discus-
sion). In Bayesian Statistics 6—Proceedings of the Sixth Valencia International Meeting
157–185. Oxford Univ. Press, New York. MR1723497
Clyde, M. and George, E. I. (2004). Model uncertainty. Statist. Sci. 19 81–94.
MR2082148
Cordell, H. J. and Clayton, D. G. (2002). A unified stepwise regression procedure
for evaluating the relative effects of polymorphisms within a gene using case/control or
family data: Application to HLA in type 1 diabetes. AJHG 70 124–141.
Cui, W. and George, E. I. (2008). Empirical Bayes vs. fully Bayes variable selection. J.
Statist. Plan. Inference 138 888–900. MR2416869
Efron, B. (2007). Correlation and large-scale simultaneous significance testing. J. Amer.
Statist. Assoc. 102 93–103. MR2293302
Flint, J. and Mackay, T. F. C. (2009). Genetic architecture of quantitative traits in
mice, flies and humans. Genome Research 19 723–733.
Gelman, A. and Rubin, D. (1992). Inference from iterative simulation using multiple
sequences. Statist. Sci. 7 457–472. MR1092987
George, E. (1999). Discussion of “Model averaging and model search strategies” by
M. Clyde. In Bayesian Statistics 6—Proceedings of the Sixth Valencia International
Meeting (J. M. Bernardo, J. O. Berger, P. Dawid and A. F. M. Smith, eds.) 157–185.
Oxford Univ. Press, Oxford.
Geyer, C. J. (1991). Markov chain Monte Carlo maximum likelihood. In Proc. 23rd
Symp. Interface. Computing Science and Statistics 156–163.
Goodman, S. N. (1999). Toward evidence-based medical statistics. 2: The Bayes factor.
Annal. Intern. Med. 130 1005–1013.
Hoeting, J. A., Madigan, D., Raftery, A. E. and Volinsky, C. T. (1999).
Bayesian model averaging: A tutorial (with discussion). Statist. Sci. 14 382–401. Cor-
rected version available at http://www.stat.washington.edu/www/research/online/
hoeting1999.pdf. MR1765176
Holland, J. H. (1975). Adaptation in Natural and Artificial Systems. Univ. Michigan
Press, Ann Arbor, MI. MR0441393
Jeffreys, H. (1961). Theory of Probability, 3rd ed. Oxford Univ. Press. MR0187257
Kass, R. E. and Raftery, A. E. (1995). Bayes factors. J. Amer. Statist. Assoc. 90
773–795.
Kooperberg, C. and Ruczinski, I. (2004). Identifying interacting SNPs using Monte
Carlo logic regression. Genetic Epidemiology 28 157–170.
Lavine, M. and Schervish, M. J. (1997). Bayes factors: What they are and what they
are not. Amer. Statist. 53 119–122. MR1707756
Ley, E. and Steel, M. F. (2009). On the effect of prior assumptions in Bayesian model
averaging with applications to growth regression. Appl. Econometrics 24 651–674.
24 M. A. WILSON ET AL.
Liang, F. andWong, W. H. (2000). Evolutionary Monte Carlo: Applications to cp model
sampling and change point problem. Statist. Sinica 10 317–342.
Lokhorst, J. and Venables, B. (2009). lasso2: L1 constrained estimation aka “lasso.”
R package version 1.2-10.
Osborne, M. R., Presnell, B. and Turlach, B. A. (2000). On the LASSO and its
dual. J. Comp. Graph. Statist. 9 319–337. MR1822089
Park, M. Y. and Hastie, T. (2008). Penalized logistic regression for detecting gene
interactions. Bioinformatics 9 30–50.
Raftery, A. E. (1986). A note on Bayes factors for log-linear contingency table models
with vague prior information. J. Roy. Statist. Soc. Ser. B 48 249–250. MR0868003
Ruczinski, I.,Kooperberg, C. and LeBlanc, M. (2003). Logic regression. J. Computat.
Graph. Statist. 12 475–511. MR2002632
Schildkraut, J. M., Moorman, P. G., Bland, A. E. and Halabi, S. (2008). Cyclin E
overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer
Epidemiology Biomarkers and Prevention 17 585–593.
Schildkraut, J. M., Goode, E. L., Clyde, M. A. and Iversen, E. S. (2009). Single
nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial
ovarian cancer. Cancer Research 69 2349–2357.
Schwender, H. and Ickstadt, K. (2007). Identification of SNP interactions using logic
regression. Biostatistics 9 187–198.
Scott, J. G. and Berger, J. O. (2010). Bayes and empirical-Bayes multiplicity adjust-
ment in the variable-selection problem. Ann. Statist. 38 2587–2619.
Servin, B. and Stephens, M. (2007). Imputation-based analysis of association studies:
Candidate regions and quantitative traits. PLOS Genetics 3.
Shi, W., Lee, K. and Wahba, G. (2007). Detecting disease-causing genes by lasso-
patternsearch algorithm. BMC Proceedings 1 Suppl 1, S60.
Stephens, M. and Balding, D. J. (2009). Bayesian statistical methods for genetic asso-
ciation studies. Nature Genet. 10 681–690.
Stephens, M., Smith, N. and Donnelly, P. (2001). A new statistical method for haplo-
type reconstruction from population data. The American Journal of Human Genetics 68
978–989.
Storey, J. (2002). A direct approach to false discovery rates. J. Roy. Statist. Soc. 64
479–498. MR1924302
Wacholder, S. (2004). Assessing the probability that a positive report is false: An ap-
proach for molecular epidemiology studies. Journal of the National Cancer Institute 96
434–442.
Wakefield, J. (2007). A Bayesian measure of the probability of false discovery in genetic
epidemiology studies. The American Journal of Human Genetics 81 208–227.
Wellcome Trust (2007). Genome-wide association study of 14,000 cases of seven com-
mon diseases and 3,000 shared controls. Nature 447 661–678.
Wilson, M. A., Iversen, E. S., Clyde, M. A., Schmidler, S. C. and Schildkraut,
J. M. (2010). Supplement to “Bayesian Model Search and Multilevel Inference for SNP
Association Studies.” DOI: 10.1214/09-AOAS322SUPP.
Wu, T. T., Chen, Y. F., Hastie, T., Sobel, E. and Lange, K. (2009). Genome-wide
association analysis by lasso penalized logistic regression. Bioinformatics 25 714–721.
MULTILEVEL INFERENCE FOR SNP ASSOCIATION STUDIES 25
M. A. Clyde
E. S. Iversen
S. C. Schmidler
M. A. Wilson
Department of Statistical Science
Duke University
Durham, North Carolina 27708-0251
USA
E-mail: clyde@stat.duke.edu
iversen@stat.duke.edu
scs@stat.duke.edu
maw27@stat.duke.edu
J. M. Schildkraut
Department of Community and Family Medicine
Duke University
Durham, North Carolina 27713
USA
E-mail: schil001@mc.duke.edu
